ArticleCancer research2011
Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells.
Article in Cancer research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Integrated analysis reveals down-regulation of SPARCL1 is correlated with cervical cancer development and progression.Cancer biomarkers : section A of Disease markers · 2018Pooled it
- Cell and Gene Therapy in Equine Ocular Disease.Veterinary ophthalmology · 2026Review
- Claudin-6 mediates an embryonic stem cell-driven antitumor response against breast cancer.iScience · 2025Article
- Footprint-free induced pluripotent stem cells can be successfully differentiated into mesenchymal stromal cells in the feline model.Stem cell research & therapy · 2025Article
- Endoplasmic reticulum stress-induced senescence in human lung fibroblasts.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers.NPJ vaccines · 2024Article
- Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T-ALL-iPSC in vivo.Cancer innovation · 2024Article
- Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors.Stem cell reviews and reports · 2023Review
- Immunization with Embryonic Stem Cells/Induced Pluripotent Stem Cells Induces Effective Immunity against Ovarian Tumor-Initiating Cells in Mice.Stem cells international · 2023Article
- Induced Pluripotent Stem Cell-Derived Corneal Cells: Current Status and Application.Stem cell reviews and reports · 2022Review
- The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma.Cancers · 2021Review
- A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy.OncoTargets and therapy · 2021Review
- Cell Fate Reprogramming in the Era of Cancer Immunotherapy.Frontiers in immunology · 2021Review
- Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine.Stem cell reviews and reports · 2020Review
- Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines.Cancers · 2020Review
- Amniotic fluid and breast milk: a rationale for breast milk stem cell therapy in neonatal diseases.Pediatric surgery international · 2020Review
- Human iPS Cells Loaded with MnONano-micro letters · 2020Article
- Fibroblast rejuvenation by mechanical reprogramming and redifferentiation.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Ultrasensitive and rapid quantification of rare tumorigenic stem cells in hPSC-derived cardiomyocyte populations.Science advances · 2020Article
- Application of Stem Cells in Stroke: A Multifactorial Approach.Frontiers in neuroscience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Pluripotent stem cells, both human embryonic stem cells (hESC) and human-induced pluripotent stem cells (hiPSC), can give rise to multiple cell types and hence have tremendous potential for regenerative therapies. However, the tumorigenic potential of these cells remains a great concern, as reflected in the formation of teratomas by transplanted pluripotent cells. In clinical practice, most pluripotent cells will be differentiated into useful therapeutic cell types such as neuronal, cardiac, or endothelial cells prior to human transplantation, drastically reducing their tumorigenic potential. Our work investigated the extent to which these differentiated stem cell derivatives are truly devoid of oncogenic potential. In this study, we analyzed the gene expression patterns from three sets of hiPSC- and hESC-derivatives and the corresponding primary cells, and compared their transcriptomes with those of five different types of cancer. Our analysis revealed a significant gene expression overlap of the hiPSC- and hESC-derivatives with cancer, whereas the corresponding primary cells showed minimum overlap. Real-time quantitative PCR analysis of a set of cancer-related genes (selected on the basis of rigorous functional and pathway analyses) confirmed our results. Overall, our findings suggested that pluripotent stem cell derivatives may still bear oncogenic properties even after differentiation, and additional stringent functional assays to purify these cells should be done before they can be used for regenerative therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.